Vaccines & Biodefense

In the U.S., the recommended immunization series prevents approximately 33,000 deaths each year. Advancements in biotechnology have made it possible to produce vaccines that cannot transmit a virus or bacterium. This method has helped create more than 20 new vaccines against infectious agents, improved existing vaccines, and increased the amount of vaccine that can be produced.

Biotech Response to COVID-19

As the threat of the novel coronavirus continues to grow globally, innovative biopharmaceutical companies are ramping up efforts to study the virus and develop vaccines and cures to protect individuals from contracting the virus.

Blog Posts
Beyond Imaagination
May 29, 2020
Our Biotechnology: Beyond Imagination series highlights the technology and scientific advancements of BIO Digital participating companies and BIO member companies. Today’s feature is Sutro Biopharma, a clinical stage…
Beyond Imaagination
May 27, 2020
Our next post in the Biotechnology: Beyond Imagination series highlights MaxCyte and the cell therapy technology the company has developed for researchers to accelerate, streamline and improve the drug development…
May 21, 2020
Biotechnology companies, large and small, are working hard to more effectively treat and safely prevent the spread of COVID-19. For an episode of the I AM BIO Podcast, BIO President & CEO Jim Greenwood was joined by…
Press Releases
May 13, 2020
Following the announcement that Dr. Moncef Slaoui will lead the Trump Administration's "Operation Warp Speed" initiative, BIO’s President and CEO, Jim Greenwood, issued the following statement:  “Dr. Moncef Slaoui is an excellent choice to lead the President’s Operation Warp Speed…
May 12, 2020
The Biotechnology Innovation Organization (BIO) today unveiled a first-of-its-kind, interactive tracker of the new treatments and vaccines in the COVID-19 pipeline. This online resource illustrates the unprecedented campaign being undertaken by biopharmaceutical innovators to combat – and…
May 11, 2020
Today, the Centers for Medicare and Medicaid Services announced that it is proposing to create a new Medicare-severity-diagnosis related group (MS-DRG) designed specifically for reimbursing providers administering CAR T-cell therapies to cancer patients. The new proposed regulation, which has been…
Letters, Comments & Testimony
April 20, 2020
Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the opportunity to submit comments on the “Draft Guidance: Nonclinical Safety Evaluation of the Immunotoxic Potential of Drugs and Biologics” (Draft Guidance or Guidance). …
April 17, 2020
April 12, 2020   Re: Docket No. FDA–2019-D-5585: FDA Draft Guidance, Bridging for Drug-Device and Biologic-Device Combination Products.   Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the opportunity to…
March 27, 2020
March 18, 2020 FDA Docket No: FDA-2019-D-4964: FDA Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Dear Sir/Madam: BIO thanks FDA for developing this additional guidance on demonstrating substantial evidence of effectiveness. BIO…
Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.